Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Avg
|
New words:
abuse, Adapted, arising, assignment, azacytidine, batch, behalf, binding, care, Chul, companion, corporate, countersuit, criteria, duty, eleven, extended, fiduciary, forward, GvHD, headcount, kind, length, Mayo, mismanagement, network, Overview, proceeding, progressing, roughly, section, standard, stayed, suspension, waste, Yang
Removed:
accelerating, Administration, affirmative, agency, Allergy, amendment, Answer, anticipation, Anticipatory, approved, arm, asserting, assertion, assumption, average, Big, blamed, cancelation, cancellation, capacity, cascade, charge, CMA, comprised, confidential, contingent, contractual, costly, CRS, data, deducting, delivered, denying, Department, depend, discovery, dismissed, Disparagement, disputing, Division, efficacy, effort, enroll, enrolled, EUA, evaluated, exercise, extremely, failure, field, filing, funding, government, health, hospitalized, hyperinflammatory, inclusive, increase, increased, inefficient, Institute, integrated, June, Kingdom, large, Libel, limited, long, longer, medical, meet, Microbiology, mitigation, nature, Neglected, negotiated, NIAID, nih, obtained, offering, offset, overseeing, owe, partially, party, placebo, population, positive, preliminary, pricing, privacy, produce, producing, program, protocol, reach, receive, recoup, reducing, referred, registrational, relief, remdesivir, represented, Savant, sensitivity, spending, sponsor, sponsored, stated, storm, strategy, subcontractor, submission, submitted, Suisse, supervising, topline, UK, underwriting, USA, weighted, written
Financial report summary
?Competition
Celgene • GSK • Jazz Pharmaceuticals • Stemline Therapeutics • ImmunityBio • Kura Oncology • Edesa Biotech • Otsuka • Kiniksa Pharmaceuticals Ltd - Ordinary Shares • IMVManagement Discussion
- At March 31, 2023, we had an accumulated deficit of $686.0 million, primarily as a result of research and development and general and administrative expenses. Since inception, we have recognized a nominal amount of revenue from payments for license or collaboration fees. While we may in the future generate additional revenue from a variety of sources, including license fees, milestone payments, and research and development payments in connection with strategic partnerships, our product candidates may never be successfully developed or commercialized and we may therefore never realize revenue from any product sales. Accordingly, we expect to continue to incur substantial losses from operations for the foreseeable future, and there can be no assurance that we will ever generate significant revenue or profits. Our ability to continue as a going concern depends on our ability to attain a significant amount of additional financing, as more fully described under “—Liquidity and Capital Resources” below and in “Risk Factors” in the 2022 Annual Report.